The effect of antibiotics on methicillin-resistant Staphylococcus aureus

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 2, 2008, Pages 246-253

  Dancer, Stephanie J ^a  

^a SOUTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Antimicrobial chemotherapy; MRSA; Virulence

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; CLOXACILLIN; COTRIMOXAZOLE; ERYTHROMYCIN; EXOTOXIN; FUSIDIC ACID; GENTAMICIN; LINEZOLID; OXACILLIN; PENICILLIN G; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STAPHYLOCOCCUS TOXIN; TEICOPLANIN; VANCOMYCIN;

ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BACTERIOPHAGE; BACTERIUM ADHERENCE; BIOFILM; DIARRHEA; DISEASE SEVERITY; DRUG EFFECT; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOLECULAR MECHANICS; MUCOSA; NONHUMAN; PATHOGENICITY; QUORUM SENSING; SKIN;

ANIMALS; ANTI-BACTERIAL AGENTS; HUMANS; METHICILLIN RESISTANCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 38349085902     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm465     Document Type: Article

References (88)

1. Rubin RJ, Harrington CA, Poon A et al. The economic impact of Staphylococcus aureus infection in New York City hospitals. Emerg Infect Dis 1999; 5: 9-17.
2. Jevons MP, Coe AW, Parker MT. Methicillin resistance in staphylocooci. Lancet 1963; 1: 904-7.
3. Cosgrove SE, Sakoulas G, Perencevich EN et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: A meta-analysis. Clin Infect Dis 2003; 36: 53-9.
4. Inoue Y, Kohno S, Fujii T at al. Clinical evaluation of catheter-related fungemia and bacteremia. Intern Med 1995; 34 485-90.
5. Kuikka A, Valtonen VV. Improved outcomes of Staphylococcus aureus bacteremia. Infect Dis Clin Pract 1994; 3: 282-7.
6. Fridkin SK, Hageman J, McDougal LK et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus auraus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis 2003; 36: 429-39.
7. Burnie J, Matthews R, Jaman-Fatami A et al. Analysis of 42 cases of septicaemia caused by an epidemic strain of methicilin-resistant Staphylococcus aureus, evidence of resistance to vancornycin. Clin Infect Dis 2000; 31: 684-9.
8. Gonzalez C, Rubio M, Romero-Vivas J et al. Bacteremic pneumonia due to Staphylocoocus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999; 29: 1171-7.
9. Blot SI, Vandewoude KH, Hoste EA et al. Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch Intern Med 2002; 162: 2229-35.
10. Harbarth S, Garbino J, Pugin J. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003; 115 529-35.
11. 1Kollef MH. Appropriate empirical antibacterial therapy for nosecomial infections. Drugs 2003; 63: 2157-68.
12. Schramm GE, Johnson JA, Doherty JA et al. Methicillin-resistant Staphylococcus aureus sterile-site infection: The importance of appropriate initial antimicrobial treatment. Crit Care Med 2006; 34: 2069-74.
13. Van der Waaij D. Colonisation resistance of the digestive tract mechanism dnd clinical consequences. Nahrung 1987; 31: 507-17.
14. Dancer SJ. How anibiotics can make us sick: The iess obvious effects of antimicrobial chemotherapy. Lancet Infect Dis 2004; 4: 611-9.
15. Monnet DL, Frimodt-Moller N. Antimicrobial-drug use and methicillin-resistant Staphylococcus aureus. Emerg infect Dis 2001; 7: 161-3.
16. Schentag JJ, Hyatt JM, Carr JR et al. Genesis of methicillin-resistant. Staphylococcus auraus (MRSA), how treatment of MRSA infections has selected for vancomycin-resistant Enterococcus faecium and the importance of antibiotic management and infection control. Clin Infect Dis 1998; 26: 129,4-14.
17. Crowcroft NS, Ronveaux O, Monnet DL et al. Methicillin-resistant Staphylococcus aureus and antimicrobial use in Belgian hospitals. Infect Control Hosp Epidemiol 1999; 20: 31-6.
18. Muller A, Mauny F, Bertin M et al. Relationship between spread of methicillin-resistant Staphylococcus aureus and antimicrobial use in a French University hospital. Clin Infect Dis 2003; 36: 971-8.
19. Hori S, Sunley R, Tami A et al. The Nottingham Staphylococcus aureus population study: Prevalence of MRSA among the elderly in a university hospital. J Hosp Infect 2002; 50: 25-9.
20. MacDougall C, Harps SE, Powell JP at et. al. Pseudomonas aeruginose, Staphylocoocus aureus, and fluoroquinolone use. Emerg Infect Dis 2005; 11: 1197-204.
21. Harbarth S, Hams AD, Carmeli Y et al. Parallel analysis of individual and aggregated data on antibiotic and exposure and resistance in Gram-negative bacilli. Clin Infect Dis 2001; 33: 1462-8.
22. Muller A, Mauny F, Talon D et al. Effect of individual- and group-level antibiotic exposure on MRSA isolation: A multilevel analysis. J Antimicrob Chemother 2006; 58: 878-81.
23. Monnet DL, MacKenzie FM, Lopez-Lozano JM et al. Antimicobial drug use and methicillin-resistant Staphylococcus aureus, Aberdeen, 1996-2000. Emerg Infect Dis 2004; 10: 1432-41.
24. Monnet DL. Methicillin-resistant Staphylococcus aureus and its relationship to antimicrobial use: Possible implications for control. Infect Control Hosp Epidemiol 1998; 19: 552-9.
25. Fukatsu K, Saito H, Matsuda T et al. Influences of type and duration of antimicrobial prophylaxis on an outbreak of methicillin-resistant Staphylococcus auraus and on the incidence of wound infection, Arch Surg 1997; 132:1320-5.
26. Charbonneau P, Parienti JJ, Thibon P et al. Fluoroquinolone use and methicillin-resistant Staphylococcus aureus isolation rates in hospitalized patients: A quasi experimental study. Clin Infect Dis 2006; 42: 778-84.
27. Finch RG, Pritchard DI, Bycroft BW et al. Quorum sensing: A novel target for anti-infective therapy. J Antimicrob Chemother 1998; 42: 569-71.
28. Donabedian H. Quorum sensing and its relevance to infectious diseases. J Infect 2003; 46: 207-14.
29. Ji G, Beavis RC, Novick RP. Cell density control of staphylococcal virulence mediated by an octapeptide pheromone. Proc Natl Acad Sci 1995; 92: 12055-9.
30. Recsei P, Kreiswirth B, O'Reilly M et al. Regulation of exoprotein expression in Staphylococcus aureus by agr. Mol Gen Genet 1986; 202: 58-61.
31. Gorske BC, Blackwell HE. Interception of quorum sensing in Staphylococcus aureus: A new niche for peptidomimetics. Org Biomol Chem 2006; 4: 1441-5.
32. MDowell P, Affas Z, Reynolds C et al. Structure, activity and evolution of the group 1 thiolactone peptide quorum-sensing system of Staphylococcus aureus. Mol Microbiol 2001; 41: 503-12.
33. Lorian V, Gemmell GC. Effect of low antibiotic concentrations on bacteria: Effects on ultrastructure, virulence, and susceptibility to immunodefenses. In: Lorian V ed. Antibiotics in Laboratory Medicine Baltimore, MD: Williams & Wilkins, 1991; 493-555.
34. Worlitzsch D, Kaygin H, Steinhuber A et al. Effects of amoxicillin, gentamicin, and moxifloxacin on the haemolytic activity of Staphylococcus aureus in vitro and in vivo. Antimicrob Agents Chemother 2001; 45: 196-202.
35. Drummond LJ, Smith DGE, Poxton IR. Effects of sub-MIC concentrations of antibiotics on growth of and toxin production by Clostridium, difficile. J Med Microbiol 2003; 52: 1033-8.
36. Bhakdi S, Tranum-Jensen J. α-Toxin of Staphylococcus aureus. Microbiol Rev 1991; 55: 733-51.
37. Kernodle DS, McGraw PA, Barg NL et al. Growth of Staphylococcus aureus with nafcillin in vitro induces α-toxin production and increases the lethal activity of sterile broth filtrates in a murine model. J Infect Dis 1995; 172: 410-9.
38. Ohlsen K, Ziebuhr W, Koller K-P et al. Effects of subinhibitory concentrations of antibiotics on a-toxin (hla) gene expression of methicillin-sensitive and methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother 1998; 42: 2817-23.
39. Boyle-Vavra S, Daum RS. Community-acquired methicillin-resistant Staphylococcus aureus: The role of Panton-Valentine leukocidin. Lab Invest 2007; 87: 3-9.
40. Lina G, Piemont Y, Godail-Gamot F et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999; 29 1128-32.
41. Dumitrescu O, Boisset S, Badiou C et al. Effect of antibiotics on Staphylococcus aureus production of Panton-Valentine leukocidin. Antimicrob Agents Chemother 2007; 51: 1515-9.
42. Ferreras M, Hoper F, Delta Serra M et al. The interaction of Staphylococcus aureus bi-component gamma-hemolysins and leucocidins with cells and lipid membranes. Biochim Biophys Acta 1998; 1414 108-26.
43. Taylor CM, Riordan FA, Graham C. Now football boots and toxic shock syndrome. BMJ 2006; 332: 1376-8.
44. Kain KC, Schulzer M, Chow AW. Clinical spectrum of non-menstrual toxic shock syndrome (TSS) comparison with menstrual TSS by multivariate discriminant analyses. Clin Infect Dis 1993; 16: 100-6.
45. Andrews M-M, Parent EM, Barry M et al. Recurrent non-menstrual toxic shock syndrome: Clinical manifestations, diagnosis, and treatment. Clin Infect Dis 2001; 32: 1471-9.
46. Kodama T, Santo T, Yokoyama T et al. Postoperative enteritis caused by methicillin-resistant Staphylococcus auraus. Surg Today 1997; 27: 816-25.
47. Gravet A, Rondeau M, Harf-Monteil C et al. Predominant Staphylococcus aureus isolated from antibiotic-associated diarrhea is clinically relevant and produces enterotoxin A and the bicomponent toxin LukE-lukD. J Clin Microbiol 1999; 37: 4012-9.
48. Altemeier WA, Hummel RP, Hill EO. Staphylococcal enteritis following therapy. Ann Surg 1963; 157: 847-58.
49. Stevens DL, Ma Y, Salmi DB et al. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 2007; 195: 202-11.
50. Herbert S, Barry P, Novick RP. Subinhibitory clindamycin differentially inhibits transcription of exoprotein genes in Staphylococcus aureus. Infect Immun 2001; 69: 2996-3003.
51. Koszczol C, Bemardo K, Kronke M et al. Subinhibitory quinupristin/ dalfopristin attenuates virulence of Staphylococcus aureus. J Antimicrob Chemother 2006; 58: 564-74.
52. Bemardo K, Pakulat N, Fleer S et al. Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression. Antimicrob Agents Chemother 2004; 48: 546-55.
53. Hastings PJ, Rosenberg SM, Slack A. Antibiotic-induced latral transfer of antibiotic resistance. Trends Microbiol 2004; 12: 401-4.
54. Maiques E, Ubeda C, Campoy S et al. β-Lactam antibiotics induce the SOS response and horizontal transfer of virulence factors in Staphylocoocus auraus. J Bacteriol 2006; 188: 2726-9.
55. Goerke C, Koller J, Wolz C. Ciprofloxacin and trimethoprim cause phage induction and virulence modulation in Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 171-7.
56. Proctor RA, Olbrantz PJ, Mosher DF. Subinhibitory concentrations of antibiotics after fibronectin binding to Staphylococcus aureus. Antimiciob Agents Chemother 1983; 24: 823-6.
57. Butcher WG, Close J. Krajewska-Pietrasik D et al. Antibiotics alter interactions of Staphylococcus aureus with collagenous substrata. Chemotherapy 1994; 40: 114-23.
58. Bisognano C, Vaudaux PE, Lew DP et al. Increased expression of fibronectin-binding proteins by fluoroquinolone-resistant Staphylococcus aureus exposed to subinhibitory levels of ciprofloxacin. Antimicrob Agents Chemother 1997; 41: 906-13.
59. Vaudaux PE, Monzillo V, Francois P et al. Introduction of the mec element (methicillin resistance) into Staphylococcus aureus alters in vitro functional activities of fibrinogen and fibronectin adhesins. Antimicrob Agents Chemother 1998; 42: 564-70.
60. Venezia RA, Domaracki BE, Evans AM et al. Selection of high-level oxacillin resistance in heteroresistant Staphylococcus aureus by fluoroquinolone exposure. J Antimicrob Chemother 2001; 48: 375-81.
61. LeBlanc L, Pepin J, Toulouse K et al. Fluoroquinolones and risk for methicillin-resistant Staphylococcus auraus, Canada. Emerg Infect Dis 2006; 12: 1398-405.
62. Williams I, Venables WA, Lloyd D et al. The effects of adherence to silicone surfaces on antibiotic susceptibility in Staphylococcus aureus. Microbiology 1997; 143: 2407-13.
63. Renzoni A, Francois P, Li D et al. Modulation of fibronectin adhesins and other virulence factors in a teicoplanin-resistant derivative of methicillin-resistant Staphyococcus aureus. Antimicrob Agents Chemother 2004; 48: 2958-65.
64. Almeida RA, Matthews KR, Cifrian E et al. Slaphylocoocus aureus invasion of bovine mammary epithelial calls. J Dairy Sci 1996; 79: 1021-6.
65. Seral C, Barcia-Macay M, Migeot-Leclercq MP et al. Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocylogenes and Staphylococcus aureus in J774 macrophages. J Antimicrob Chemother 2005; 55: 511-7.
66. Krut O, Sommer H, Kronke M. Antibiotic-induced persistence of cytotoxic Staphylococcus aureus in non-phagocytic cells. J Antimicro Chemother 2004; 52: 167-73.
67. Sendi P, Rohrbach M, Graber P et al. Staphylococcus aureus small colony variants in prosthetic joint infection. Clin Infect Dis 2006; 43: 961-7.
68. Broillette E, Martinez A, Boyll BJ. Persistence of a Staphylococcus aureus small-colony variant under antibiotic pressure. FEMS Immunol Med Microbiol 2004; 41: 35-41.
69. Vaudaux P, Kelley WL, Lew DP. Staphylococcus aureus small colony variants: Difficult to diagnose and difficult to treat. Clin Infect Dis 2006; 43: 968-70.
70. Seaman PF, Ochs D, Day MJ. Comment on: Triclosan resistance in methicillin-resistant Staphylococcus aureus expressed as small colony variants: A novel mode of evasion of susceptibility to antiseptics. J Antimicrob Chemother 2007; 60: 175-6.
71. Lindsay D, von Holy A. Bacterial biofilms within the clinical setting: what healthcare professionals should know. J Hosp Infect 2006; 64: 313-25.
72. Chuard C, Vaudaux PE, Proctor RA et al. Decreased susceptibility to antibiotic killing of a stable small colony variant of Staphylococcus aureus in fluid phase and on fibronectin-coated surfaces. J Antimicrob Chemother 1997; 39: 603-8.
73. Langsrud S, Sidhu MS, Heir E et al. Bacterial disinfectant resistance - a challenge for the food industry. Int Biodeterioration Biodegrad 2003; 51: 283-90.
74. Rozgonyi F, Kocsis E, Kristof K et al. Is MRSA more virulent than MSSA? Clin Microbiol Infect 2007; 13: 843-5.
75. Libert M, Elkholti M, Massaut J et al. Risk factors for meticillin resistance and outcome of StaphylooDccus aureus bloodstream infection in a Belgian university hospital. J Hosp Infect 2007; doi: 10. 1011/j.jhin.2007.08.021, in press.
76. Sakoulas G, Gold HS, Cohen RA et al. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J Antimicrob Chemother 2006; 57: 699-704.
77. Schrader-Fischer G, Berger-Bachi B. The AbcA transporter of Staphylococcus aureus affects autolysis. Antimicrob Agents Chemother 2001; 45: 407-12.
78. Dancer SJ. The problem with caphalosporins. J Antimicrob Chemother 2001; 48: 463-78.
79. Kemodle DS, Classen DC, Stratton CW et al. Association of borderline oxacillin-susceptible strains of Staphylococcus aureus with surgical wound infections. J Clin Microbiol 1998; 36: 219-22.
80. Anonymous. Four paediatric deaths from community-acquired MRSA-Minnesota and North Dakota, 1997-1999. MMWR 1999; 48: 707-10.
81. Feder HM. Methicillin-resistant Staphylococcus aureus infections in 2 pediatric patients. Arch Fam Med 2000; 9: 560-2.
82. Anonymous. Severe methicillin-resistant Staphylocoocus aureus community-acquired pneumonia associated with influenza - Louisiana and Georgia, December 2006-January 2007. MMWR 2007; 56: 325-9.
83. MacKenzie FM, Bruce J, Struelehs MJ et al. Antimicrobial drug use and infection control practices associated with the-prevalence of methicillin-resistant Staphylococcus aureus in European hospitals. Clin Microbiol Infect 2007; 13: 269-76.
84. Bemtsen C, McDermott W. Increased transmissibility of staphylococci to patients receiving an antimicrobial drug. N Engl J Med 1960; 262: 637-42.
85. Boyce JM, Potter-Byhoe G, Chenevett C et al. Environmental contamination due to methicillin-resistant Staphylococcus aureus: possible infection control implications. Infect Control Hosp Epidemiol 1997; 18: 622-7.
86. Holden MTG, Feil EJ, Lindsay JA et al. Complete genomes of two clinical Staphylococcus aureus strains: Evidence for the rapid evolution of virulence and drug resistance. Proc Natl Acad Sci USA 2004; 101: 9786-91.
87. Dancer SJ. Importance of the environment in meticillin-resistant Staphylococcus aureus acquisition: The case for hospital cleaning. Lancet Infect Dis 2007; doi:10.1016/S1473-3099(07)70241-4, in press.
88. Cars H, Hakansson A. To prescribe - or not to prescribe - antibiotics. District physicians' habits vary greatly, and are difficult to change. Scand J Prim Health Care 1995; 13: 3-7.